BioFire® FilmArray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial
Open Access
- 13 June 2021
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 10 (3) , 1437-1449
Abstract
Introduction The epidemiology of severe lower respiratory tract infections (LRTI) is constantly changing. We aimed to describe it using the BioFire® FilmArray® Pneumonia plus (PNplus) Panel. Methods In a sub-study of the PROGRESS trial, sputum samples of 90 patients with sepsis and LRTI were retrospectively studied. The primary endpoint was the comparative detection rate of pathogens between conventional microbiology and PNplus Panel; secondary endpoints were microbiology and the association with the inflammatory host response. Results Fifty-six patients with community-acquired pneumonia without risk factors for multidrug-resistant (MDR) pathogens and another 34 patients with risk factors for MDR were studied; median pneumonia severity index (PSI) was 113 (88–135). PNplus detection rate was 72.2% compared to 10% by conventional microbiology (p < 0.001); Streptococcus pneumoniae was the most common pathogen. PSI and procalcitonin were greater among patients with bacterial pathogens than viral pathogens. Median procalcitonin was 0.49 ng/ml and 0.18 ng/ml among patients with ≥ 105 and < 105 copies/ml of detected bacteria, respectively (p = 0.004). Resistance reached 14.4%. Conclusion PNplus detects severe pneumonia pathogens at a greater rate than conventional microbiology. High levels of inflammation accompany bacterial detection. Trial Registration PROGRESS, ClinicalTrials.gov NCT03333304, 06/11/2017.Keywords
Funding Information
- Hellenic Institute for the Study of Sepsis
- bioMérieux
This publication has 18 references indexed in Scilit:
- Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trialClinical Microbiology and Infection, 2019
- The burden of community-acquired bacterial pneumonia in the era of antibiotic resistanceExpert Review of Respiratory Medicine, 2018
- Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysisThe Lancet Infectious Diseases, 2018
- Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trialThe Lancet Respiratory Medicine, 2017
- Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic SocietyClinical Infectious Diseases, 2016
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Antibiotic Discontinuation Rates Associated with Positive Respiratory Viral Panel and Low Procalcitonin Results in Proven or Suspected Respiratory InfectionsInfectious Diseases and Therapy, 2015
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. AdultsNew England Journal of Medicine, 2015
- Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract InfectionsJAMA, 2009